ArticleJournal of thoracic disease2026
Survival trends in extensive-stage small cell lung cancer in the pre-immunotherapy and immunotherapy eras: a population-based SEER study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extensive-stage small cell lung cancer (ES-SCLC) is a highly aggressive malignancy with limited treatment options. Immune checkpoint inhibitors (ICIs) have marked the beginning of the immunotherapy era for SCLC. However, population-level survival trends following the introduction of immunotherapy remain unclear. Methods: We conducted a retrospective study using Surveillance, Epidemiology, and End Results (SEER) data from 2015 to 2021 to analyze survival outcomes in ES-SCLC patients before (2015-2017) and after (2019-2021) the introduction of ICIs. We employed propensity score matching (PSM) to adjust for confounding factors and used Cox regression models to identify prognostic factors. Kaplan-Meier analysis and log-rank tests were used to assess overall survival (OS) and cancer-specific survival (CSS). Results: A total of 7,214 patients were included. After PSM, patients diagnosed in the 2019-2021 cohort demonstrated significantly improved survival compared with those diagnosed in the 2015-2017 cohort. The median overall survival (mOS) improved from 4.0 months [95% confidence interval (CI): 4.0-4.0] in the pre-immunotherapy era to 5.0 months (95% CI: 4.0-5.0) in the post-immunotherapy era [hazard ratio (HR) =0.849, 95% CI: 0.800-0.902; P<0.001], indicating that patients diagnosed during the immunotherapy era experienced better survival than those diagnosed during the pre-immunotherapy era. Marital status, geographical area, and metastasis sites were identified as significant prognostic factors. Notably, brain metastasis did not significantly affect survival, likely due to advancements in treatment. Conclusions: Patients diagnosed during the immunotherapy era showed improved survival compared with those diagnosed during the pre-immunotherapy era. Socio-economic and geographical factors also play a critical role in prognosis, suggesting that personalized treatment strategies are essential for optimal patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.